Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alprostadil + beraprost
- Development stage
- Phase 4
- Lead developer
- China-Japan Friendship Hospital
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
The combination of alprostadil and a prostacyclin analogue, specifically beraprost sodium, is a therapeutic regimen extensively studied and utilized by the China-Japan Friendship Hospital for the management of diabetic nephropathy. Alprostadil is a synthetic form of prostaglandin E1 (PGE1) that acts as a potent vasodilator and inhibitor of platelet aggregation by activating prostaglandin E (EP) receptors. Beraprost sodium is an orally active analogue of prostacyclin (PGI2) that mimics its effects by binding to the prostaglandin I2 (IP) receptor. This combination therapy aims to synergistically improve renal microcirculation, reduce glomerular capillary pressure, and decrease urinary protein excretion. By modulating prostaglandin signaling pathways, the treatment helps protect the glomerular filtration barrier and mitigate inflammatory and fibrotic processes in the kidneys of patients with diabetes.
- Brand names
- KaishiKainaProstandin
- Other names
- alprostadil + prostacyclin analoguePGE1 + PGI2 analoguealprostadil + beraprost sodium
02
Targets
PTGER1 (Prostaglandin E Receptor 1)PTGER2 (Prostaglandin E2 receptor EP2)PTGER3 (Prostaglandin E2 receptor EP3 subtype)PTGER4 (Prostaglandin E2 receptor EP4 subtype)PTGIR (Prostanoid IP Receptor)
Beyond the preview
Go deeper on alprostadil + beraprost.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alprostadil + beraprost.